Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × urelumab × Dermatologic × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

Ipilimumab 100 pembrolizumab 99 Nivolumab 99 aldesleukin 69 Cyclophosphamide 63 fludarabine phosphate 47 Interleukin-2 42 Temozolomide 33 Dacarbazine 32 trametinib 31 Bevacizumab 28 fludarabine 27 dabrafenib 27 Radiotherapy 27 sargramostim 25 incomplete Freund's adjuvant 25 Vemurafenib 24 Radiosurgery 24 Paclitaxel 20 Carboplatin 20 binimetinib 19 atezolizumab 18 Peripheral Blood Stem Cell Transplantation 18 Biopsy 18 Aminolevulinic Acid 18 encorafenib 17 Mycophenolic Acid 17 HhAntag691 16 cobimetinib 15 Tacrolimus 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡